Miprosed (Midazolam)

Midazolam, the active ingredient in Miprosed, is a benzodiazepine presented as an oral formulation for oral use. It provides rapid sedation, anxiolysis, anticonvulsant and muscle‑relaxant effects for patients who need short‑term control of anxiety, pre‑operative preparation, procedural sedation, insomnia or seizure management.

GNH USA supplies Miprosed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Midazolam is a benzodiazepine that acts on the central nervous system to provide sedation and anxiolysis.

- Anxiety: reduces acute anxiety symptoms and promotes calmness in short‑term situations. - Pre‑operative sedation: facilitates patient relaxation and amnesia before surgical procedures. - Procedural sedation: enables safe, controlled sedation during minor diagnostic or therapeutic interventions. - Insomnia: induces sleep onset for patients with transient sleep disturbances. - Seizure control: aborts acute seizure activity and provides adjunctive anticonvulsant effect.

Midazolam may cause a range of adverse reactions, from mild to severe, depending on dose, patient factors and concomitant medications.

Common Side Effects: - Drowsiness - Dizziness - Impaired coordination - Amnesia

Serious or Rare Side Effects: - Respiratory depression - Severe allergic reaction (anaphylaxis) - Paradoxical agitation or aggression

Midazolam requires careful clinical assessment and monitoring to minimise risks.

- Assess respiratory function: evaluate baseline breathing status before administration. - Use caution in the elderly: lower doses may be needed due to increased sensitivity. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal seizures. - Monitor for dependence: limit duration of use and assess for signs of misuse. - Contraindicated in severe obstructive sleep apnea: risk of profound respiratory compromise. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Midazolam interacts with several drug classes that can amplify its sedative properties or alter its plasma concentration.

Major Interactions (Avoid): - Opioids: additive respiratory depression and profound sedation. - CNS depressants (e.g., barbiturates, alcohol): increased risk of excessive sedation and respiratory compromise. - Antifungal azoles (ketoconazole, itraconazole): inhibition of metabolism leading to higher midazolam levels.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome when combined with serotonergic agents. - Anticonvulsants (phenytoin, carbamazepine): induction of metabolism may reduce midazolam efficacy.